Wall Street analysts expect Galena Biopharma, Inc. (NASDAQ:GALE) to report ($0.15) earnings per share (EPS) for the current quarter, according to Zacks. Zero analysts have issued estimates for Galena Biopharma’s earnings. Galena Biopharma reported earnings of ($0.40) per share in the same quarter last year, which would suggest a positive year-over-year growth rate of 62.5%. The business is expected to report its next quarterly earnings results on Wednesday, November 8th.
According to Zacks, analysts expect that Galena Biopharma will report full-year earnings of ($0.59) per share for the current financial year. For the next fiscal year, analysts expect that the firm will report earnings of ($0.84) per share. Zacks’ earnings per share averages are a mean average based on a survey of analysts that follow Galena Biopharma.
Galena Biopharma (NASDAQ:GALE) last announced its quarterly earnings results on Monday, August 14th. The biotechnology company reported ($0.16) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.15) by $0.01. During the same quarter in the prior year, the firm posted $0.05 EPS.
A number of analysts have issued reports on the company. Maxim Group reaffirmed a “hold” rating on shares of Galena Biopharma in a report on Wednesday, August 9th. Zacks Investment Research downgraded Galena Biopharma from a “buy” rating to a “hold” rating in a research report on Tuesday, May 16th. Finally, ValuEngine downgraded Galena Biopharma from a “sell” rating to a “strong sell” rating in a research report on Friday, June 2nd.
Several hedge funds have recently made changes to their positions in GALE. Virtu KCG Holdings LLC increased its stake in shares of Galena Biopharma by 677.4% in the second quarter. Virtu KCG Holdings LLC now owns 224,050 shares of the biotechnology company’s stock worth $130,000 after buying an additional 195,230 shares in the last quarter. Vanguard Group Inc. increased its stake in shares of Galena Biopharma by 1.0% in the second quarter. Vanguard Group Inc. now owns 1,332,434 shares of the biotechnology company’s stock worth $774,000 after buying an additional 13,302 shares in the last quarter. Finally, Renaissance Technologies LLC purchased a new stake in shares of Galena Biopharma during the first quarter worth approximately $976,000. Institutional investors own 21.73% of the company’s stock.
Shares of Galena Biopharma (NASDAQ:GALE) traded down 2.9723% during trading on Wednesday, reaching $0.3395. 343,539 shares of the company’s stock traded hands. The company has a 50 day moving average price of $0.50 and a 200 day moving average price of $0.59. The stock’s market capitalization is $13.04 million. Galena Biopharma has a 1-year low of $0.26 and a 1-year high of $9.10.
Galena Biopharma Company Profile
Galena Biopharma, Inc is a biopharmaceutical company. The Company focuses on developing and commercializing targeted oncology therapeutics that address unmet medical needs. The Company’s development portfolio ranges from mid- to late-stage clinical assets, including cancer immunotherapy program led by NeuVax (nelipepimut-S), GALE-301 and GALE-302.
Get a free copy of the Zacks research report on Galena Biopharma (GALE)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Galena Biopharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galena Biopharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
